Consumer health care products and medical devices generate billions of dollars for Johnson & Johnson. Its pharmaceutical offerings are expected to drive the company’s growth in the year ahead, with its blockbuster blood thinner Xarelto among the leaders of the pack, according to analyst Todd Campbell, owner of E.B. Capital Markets, LLC. Xarelto, manufactured by J&J unit Janssen Pharmaceuticals and Bayer, was approved in 2011 as the second in a new class of blood thinners competing with the long-used warfarin for the prevention of strokes in patients with atrial fibrillation. The medication is also used to treat deep vein thrombosis ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.